Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have an ECOG/Zubrod performance status of =\< 2~* Patient must have a histologic diagnosis of primary GIST (without peritoneal or distant metastasis) that expresses Kit protein by immunohistochemistry and have tumor size \>= 3cm in maximum dimension~* Patient must have undergone complete gross resection (includes R0 \[negative microscopic margins\] and R1 \[positive microscopic margins\]) of a primary GIST within 70 days prior to registration~* Patient must have a chest x-ray completed within 28 days prior to registration; NOTE: Chest CT within 28 days prior to registration can be used in lieu of chest x-ray~* Patient must have a post-operative CT scan with IV and PO contrast or MRI with contrast (if allergic to CT contrast) of abdomen and pelvis within 28 days prior to registration~* Creatinine =\< 1.5 times the institution ULN~* WBC \>= 2,000/mm\^3~* Platelets \>= 100,000/mm\^3~* Total Bilirubin =\< 1.5 times the institution ULN; NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study~* AST =\< 2.5 times the institution ULN~* ALT =\< 2.5 times the institution ULN~* Female of childbearing potential must have negative serum pregnancy test; NOTE: Post-menopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential~* Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures~* Patient must provide written authorization to allow the use and disclosure of their protected health information; NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration (non-US sites are exempt from HIPAA regulations)~* If patient is a cancer survivor, ALL of the following criteria apply:~  * Patient has undergone potentially curative therapy for all prior malignancies~ * No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone)~ * Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies~Exclusion Criteria:~* Patient has received post-operative chemotherapy~* Patient has received post-operative radiation therapy~* Patient has received post-operative investigational treatment~* Patient has received prior therapy with STI571~* Patient has had an active infection requiring antibiotics within 14 days prior to registration~* Patient has objective evidence of residual disease on the postoperative CT scan or MRI of the abdomen or pelvis~* Patient, if female and breastfeeding; NOTE: It is not known whether STI571or its metabolites are excreted in human milk; however, in lactating female rats administered 100mg/kg, a dose approximately equal to the maximum clinical dose of 800mg/day based on body surface area, STI571 and /or its metabolites were extensively excreted in milk; it is estimated that approximately 1.5% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight; women should be advised against breastfeeding while taking STI571~* Patient has New York Heart Association class 3 or 4 cardiac disease~* Patient is taking full dose warfarin; NOTE: The use of mini-dose warfarin (1mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (imatinib mesylate) (Type: EXPERIMENTAL): Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).